GHAPPcast: The Clinical Utility of Guselkumab in CD
GHAPPcast31 Mars 2025

GHAPPcast: The Clinical Utility of Guselkumab in CD

Thank you to Johnson & Johnson for your support of this GHAPPcast episode.

Join host Gabriella McCarty, NP-C, and special guest Teddy Solomon, NP, from Cedars-Sinai, for an in-depth discussion on The Clinical Utility of Guselkumab in Crohn’s Disease. In this episode of GHAPPcast—the official podcast of the Gastroenterology & Hepatology Advanced Practice Providers (GHAPP)—we examine how this IL-23 inhibitor may fit into the evolving treatment landscape for patients with Crohn’s disease.

Teddy, a recognized IBD expert and plenary speaker at the recent GHAPP National Conference, shares clinical insights, trial data, and personal perspectives on the unique mechanism of action behind guselkumab. You’ll learn about its potential role in induction and maintenance therapy, the results of the GRAVITI and GALAXI trials, and how it compares to other therapies like ustekinumab and risankizumab. We also explore which patient profiles may benefit most from guselkumab and which scenarios may call for a different approach.

Whether you're biologic-naive or exploring options beyond TNF inhibitors, this episode will give you tools to navigate shared decision-making and better support patients through personalized IBD care.

Subscribe to GHAPPcast on your favorite podcast platform, and visit ghapp.org for more expert-led resources and clinical tools for APPs in GI and hepatology.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(155)

FAQ: QUASAR Long Term Extension Interim Analysis

FAQ: QUASAR Long Term Extension Interim Analysis

Thank you to Johnson & Johnson for their support on this FAQ Video Module. In this educational video, Jamie Brogan, APRN, from Northwestern Medicine, reviews the latest QUASAR long-term extension data...

2 Juni 4min

Medication Review: Guselkumab IV vs SC Formulation

Medication Review: Guselkumab IV vs SC Formulation

Thank you to Johnson & Johnson for their support on this Medication Review Video Module. In this quick educational video, Angelina Collins, NP, from the University of California San Diego Inflammatory...

28 Maj 3min

FAQ: Recognizing OHE Risk in Patients with Chronic Liver Disease

FAQ: Recognizing OHE Risk in Patients with Chronic Liver Disease

Thank you to Salix for the support on this FAQ Video Module.This educational FAQ module, featuring Mikhail Alper, PA-C focuses on recognizing risk factors and early clinical indicators of Overt Hepati...

26 Maj 2min

FAQ: Phase 3 GALAXI 2 & 3: Extraintestinal Manifestations In Moderate to Severe Crohn’s Disease

FAQ: Phase 3 GALAXI 2 & 3: Extraintestinal Manifestations In Moderate to Severe Crohn’s Disease

Thank you to Johnson & Johnson for the support on this FAQ Video Module.This FAQ video features Janette Villalon, PA, who reviews the role of guselkumab in treating extraintestinal manifestations in p...

19 Maj 5min

Medication Review: Monotherapy vs. Combination Therapy: Relevance in IBD Treatment Strategy

Medication Review: Monotherapy vs. Combination Therapy: Relevance in IBD Treatment Strategy

Thank you to Celltrion for the support on this Medication Review Video Module.This medication review explores the evolving role of monotherapy versus combination therapy in the treatment of inflammato...

14 Maj 3min

Medication Review: Stable PK Supporting Continuous Inflammatory Control

Medication Review: Stable PK Supporting Continuous Inflammatory Control

Thank you to Celltrion for the support on this Medication Review Video Module.This medication review explores the role of stable pharmacokinetics (PK) in achieving continuous inflammatory control in i...

7 Maj 6min

Journal Club: ASTRO Phase 3 Study: Efficacy and Safety of SC Guselkumab

Journal Club: ASTRO Phase 3 Study: Efficacy and Safety of SC Guselkumab

Thank you to Johnson & Johnson for the support on this Journal Club Review Module.In this journal club video, Sharon Dudley Brown, CRNP, PhD, from the IBD Center at Johns Hopkins University, reviews t...

28 Apr 5min

Journal Club: Benefit–Risk Profile of Upadacitinib in Patient’s With Moderate to Severe UC and CD

Journal Club: Benefit–Risk Profile of Upadacitinib in Patient’s With Moderate to Severe UC and CD

Thank you to AbbVie for the support on this Journal Club Review Module.This journal club review episode explores the benefit–risk profile of Upadacitinib for patients with moderately to severely activ...

21 Apr 23min

Populärt inom Hälsa

somna-med-henrik
rss-bara-en-till-om-missbruk-medberoende-2
rss-vuxna-pa-latsas
inga-beiga-morsor
angestpodden
sexnoveller-deluxe
johannes-hansen-podcast
rss-viktmedicinpodden
rss-jossan-nina
sova-med-dan-horning
rss-the-house-podcast-3
rss-basta-livet
not-fanny-anymore
rss-relationsrevolutionen
sex-pa-riktigt-med-marika-smith
sa-in-i-sjalen
brottarbroder
rss-activation-podcast
rss-sjalsligt-avkladd
rss-fet-fakta-podcast